Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients
Prafull Raheja, Angela Price, Zhongyun Wang, Debbie Arbique, Beverley Adams-Huet, Richard J Auchus, Wanpen Vongpatanasin, Prafull Raheja, Angela Price, Zhongyun Wang, Debbie Arbique, Beverley Adams-Huet, Richard J Auchus, Wanpen Vongpatanasin
Abstract
Recent studies from our laboratory indicate that chlorthalidone triggers persistent activation of the sympathetic nervous system and promotes insulin resistance in hypertensive patients, independent of serum potassium. Mechanisms underlying these adverse effects of chlorthalidone remain unknown, but increasing evidence in rodents suggests the role of angiotensin and aldosterone excess in inducing both sympathetic overactivity and insulin resistance. Accordingly, we conducted studies in 17 subjects with untreated stage 1 hypertension, measuring sympathetic nerve activity at baseline and after 12 weeks of chlorthalidone alone (25 mg/d), chlorthalidone plus spironolactone, and chlorthalidone plus irbesartan, using randomized crossover design. We found that chlorthalidone alone decreased 24-hour ambulatory blood pressure from 135±3/84±2 to 124±2/78±2 mm Hg and significantly increased sympathetic nerve activity from baseline (from 41±3 versus 49±4 bursts per minute; P<0.01). The addition of spironolactone to chlorthalidone returned sympathetic nerve activity value to baseline (42±3 bursts per minute; P>0.05), whereas the addition of irbesartan failed to alter the sympathetic nerve activity response to chlorthalidone in the same subjects (52±2 bursts per minute; P<0.01) despite a similar reduction in ambulatory blood pressure (121±2/75±2 and 121±2/75±2 mm Hg, respectively). Chlorthalidone alone also increased indices of insulin resistance, which was not observed when used in combination with spironolactone. In conclusion, our study demonstrates beneficial effects of spironolactone in attenuating both chlorthalidone-induced sympathetic activation and insulin resistance in humans, independent of blood pressure reduction. Because sympathetic overactivity and insulin resistance contribute to the poor prognosis in patients with cardiovascular disease, combination therapy of chlorthalidone with mineralocorticoid receptor antagonists may constitute a preferable regimen than chlorthalidone alone in hypertensive patients.
Trial registration: ClinicalTrials.gov NCT00353652.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3401321/bin/nihms388407f1.jpg)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3401321/bin/nihms388407f2.jpg)
Figure 3
Summary data showing changes in…
Figure 3
Summary data showing changes in fasting plasma glucose (left), HOMA-IR (middle), and serum…
- Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low?Leenen FH, Ruzicka M, Floras JS. Leenen FH, et al. Hypertension. 2012 Aug;60(2):278-80. doi: 10.1161/HYPERTENSIONAHA.112.197012. Epub 2012 Jun 25. Hypertension. 2012. PMID: 22733463 No abstract available.
- Emerging pain ameliorating effects of spironolactone: an additional benefit of its use in hypertensive and cardiac patients: recent insights.Kapoor S. Kapoor S. Hypertension. 2012 Dec;60(6):e42. doi: 10.1161/HYPERTENSIONAHA.112.203026. Epub 2012 Oct 15. Hypertension. 2012. PMID: 23071128 No abstract available.
- Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients.Menon DV, Arbique D, Wang Z, Adams-Huet B, Auchus RJ, Vongpatanasin W. Menon DV, et al. J Clin Endocrinol Metab. 2009 Apr;94(4):1361-6. doi: 10.1210/jc.2008-2660. Epub 2009 Jan 21. J Clin Endocrinol Metab. 2009. PMID: 19158191 Free PMC article. Clinical Trial.
- Negative effects of chlorthalidone on sympathetic nervous system and insulin resistance in hypertensive patients may be avoided with spironolactone: further studies are still needed.Castro-Torres Y, Fleites-Pérez A, Carmona-Puerta R, Jiménez-Garrido RG. Castro-Torres Y, et al. Ir J Med Sci. 2015 Dec;184(4):727-9. doi: 10.1007/s11845-015-1350-1. Epub 2015 Sep 4. Ir J Med Sci. 2015. PMID: 26341505 Review.
- Central sympathetic inhibition by mineralocorticoid receptor but not angiotensin II type 1 receptor blockade: are prescribed doses too low?Leenen FH, Ruzicka M, Floras JS. Leenen FH, et al. Hypertension. 2012 Aug;60(2):278-80. doi: 10.1161/HYPERTENSIONAHA.112.197012. Epub 2012 Jun 25. Hypertension. 2012. PMID: 22733463 No abstract available.
- Emerging pain ameliorating effects of spironolactone: an additional benefit of its use in hypertensive and cardiac patients: recent insights.Kapoor S. Kapoor S. Hypertension. 2012 Dec;60(6):e42. doi: 10.1161/HYPERTENSIONAHA.112.203026. Epub 2012 Oct 15. Hypertension. 2012. PMID: 23071128 No abstract available.
- Angiotensin receptor blockers: new considerations in their mechanism of action.Sica DA. Sica DA. J Clin Hypertens (Greenwich). 2006 May;8(5):381-5. doi: 10.1111/j.1524-6175.2005.05141.x. J Clin Hypertens (Greenwich). 2006. PMID: 16687949 Free PMC article. Review.
- Differential effects of eplerenone versus amlodipine on muscle metaboreflex function in hypertensive humans.Peri-Okonny PA, Velasco A, Lodhi H, Wang Z, Arbique D, Adams-Huet B, Iwamoto G, Mitchell JH, Mizuno M, Smith S, Vongpatanasin W. Peri-Okonny PA, et al. J Clin Hypertens (Greenwich). 2021 Sep;23(9):1706-1714. doi: 10.1111/jch.14333. Epub 2021 Aug 25. J Clin Hypertens (Greenwich). 2021. PMID: 34432358 Free PMC article. Clinical Trial.
- Mineralocorticoid receptors in the pathogenesis of insulin resistance and related disorders: from basic studies to clinical disease.Jia G, Lockette W, Sowers JR. Jia G, et al. Am J Physiol Regul Integr Comp Physiol. 2021 Mar 1;320(3):R276-R286. doi: 10.1152/ajpregu.00280.2020. Epub 2021 Jan 13. Am J Physiol Regul Integr Comp Physiol. 2021. PMID: 33438511 Free PMC article. Review.
- Characterization of the inflammatory-metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease.Packer M, Lam CSP, Lund LH, Maurer MS, Borlaug BA. Packer M, et al. Eur J Heart Fail. 2020 Sep;22(9):1551-1567. doi: 10.1002/ejhf.1902. Epub 2020 Jun 26. Eur J Heart Fail. 2020. PMID: 32441863 Free PMC article. Review.
- Alterations in Glucose Metabolism During the Transition to Heart Failure: The Contribution of UCP-2.Kutsche HS, Schreckenberg R, Weber M, Hirschhäuser C, Rohrbach S, Li L, Niemann B, Schulz R, Schlüter KD. Kutsche HS, et al. Cells. 2020 Feb 27;9(3):552. doi: 10.3390/cells9030552. Cells. 2020. PMID: 32120777 Free PMC article.
- [Blood pressure targets in patients with diabetes mellitus : What are optimum values?].Dederer J, Bewarder Y, Mahfoud F, Böhm M. Dederer J, et al. Herz. 2019 May;44(3):231-237. doi: 10.1007/s00059-019-4796-5. Herz. 2019. PMID: 30847509 German.
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
- Action Potentials / drug effects
- Action Potentials / physiology
- Angiotensin II Type 1 Receptor Blockers / pharmacology
- Biphenyl Compounds / pharmacology
- Chlorthalidone / pharmacology*
- Cross-Over Studies
- Diuretics / pharmacology
- Drug Therapy, Combination
- Female
- Heart Rate / drug effects
- Heart Rate / physiology
- Humans
- Hypertension / classification
- Hypertension / physiopathology*
- Insulin Resistance / physiology*
- Irbesartan
- Male
- Microelectrodes
- Middle Aged
- Spironolactone / pharmacology*
- Sympathetic Nervous System / drug effects*
- Sympathetic Nervous System / physiology*
- Tetrazoles / pharmacology
- Treatment Outcome
- Angiotensin II Type 1 Receptor Blockers
- Biphenyl Compounds
- Diuretics
- Tetrazoles
- Spironolactone
- Irbesartan
- Chlorthalidone
- ClinicalTrials.gov/NCT00353652
- Full Text Sources
- Medical
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3401321/bin/nihms388407f3.jpg)
Source: PubMed